Non-invasive profiling of the tumour microenvironment with spatial ecotypes
A blood test capturing tumor structure through DNA patterns may help predict which melanoma patients benefit from immunotherapy without invasive biopsies.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Enabling DCIS subtyping
AI analysis of routine breast cancer slides could spare low-risk patients from surgery by reliably identifying those safe for monitoring instead.
Novel or significantly improved treatmentTwo decades of PARP inhibitor synthetic lethality in cancer
PARP inhibitors represent a landmark precision medicine success for BRCA-mutant cancers, with emerging strategies to extend synthetic lethality beyond BRCA.
Promising but preliminaryDiscovery of a paralog-selective p300 protein degrader with potent…
A new protein-degrading drug targets AML and lymphoma while avoiding toxicity that plagued earlier dual-target approaches, suggesting safer hematologic cancer options.
Promising but preliminaryMitochondrial RNA helicase DDX28 promotes cell cycle and DNA repair…
A mitochondrial protein linked to poor outcomes in AML may unlock new therapeutic targets at the intersection of cell metabolism and immune suppression.